Cosentyx has since been joined by other IL-17 inhibitors including Eli Lilly's Taltz (ixekizumab) and Bausch Health's Siliq/Kyntheum (brodalumab), but UCB is convinced it can make headway in the ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

The newer biologics — interleukin (IL)-17, IL-12/23, and IL-23 inhibitors — have cardiovascular safety profiles comparable with those of tumor necrosis factor (TNF) inhibitors in biologic ...

The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

However, significant research has been completed on IL-17 inhibitors like lutikizumab, izokibep, and sonelokimab. Additional research is needed to determine which patients have the most robust ...